What's Hot in Cardiology beyond DES? Try Structural Heart Disease

Structural heart disease was prominently featured during the Emerging Technologies Symposium held during this year's Summer in Seattle cardiovascular conference.

The ever-increasing number of clinical conferences, particularly in cardiology, can sometimes take on a mind-numbing sameness as attendees sit through the presentation of still another patient subset of a drug-eluting stent (DES). What distinguishes the annual Summer in Seattle meeting is the Emerging Technologies Symposium held as part of the conference, at which future areas of interest within cardiology are identified and early-stage companies active in that space are given the opportunity to make presentations. Mark Reisman, MD, of Seattle's Swedish Medical Center, and William A. Gray, MD, of Columbia University Medical Center , the conference directors, have been successful in highlighting the next and the next-next areas of interest in cardiovascular medicine and have been able to attract very early-stage companies to discuss those areas, no small feat when it comes to device start-ups.

The fifth annual conference, held this July, highlighted a range of topics from vascular technologies such as bioabsorbable DES to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

‘A Small Medtech Industry Ecosystem With An Outsized Global Influence’

 
• By 

Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.

Dealmaking Quarterly Statistics, Q2 2025

 
• By 

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By 

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.